

**TITLE:** Pre-Existing Comorbidities Diminish the Likelihood of Seropositivity After SARS-CoV-2 Vaccination

**SHORT TITLE:** COMORBIDITY & SARS-COV-2 SEROSTATUS

**ARTICLE TYPE:** Communication

**AUTHORS:**

Alok R. Amraotkar<sup>1</sup>, Adrienne M. Bushau-Sprinkle<sup>2</sup>, Rachel J. Keith<sup>1</sup>, Krystal T. Hamorsky<sup>2</sup>, Kenneth E. Palmer<sup>2</sup>, Hong Gao<sup>1</sup>, Shesh N. Rai<sup>3-5</sup>, and Aruni Bhatnagar<sup>1,3\*</sup>

**AFFILIATIONS:**

<sup>1</sup>Division of Environmental Medicine, Christina Lee Brown Envirome Institute, University of Louisville School of Medicine, Louisville, KY, 40202 USA; [alok.amraotkar@louisville.edu](mailto:alok.amraotkar@louisville.edu)

(A.R.A); [rachel.keith@louisville.edu](mailto:rachel.keith@louisville.edu) (R.J.K); [hong.gao@louisville.edu](mailto:hong.gao@louisville.edu) (H.G);

[Aruni@Louisville.edu](mailto:Aruni@Louisville.edu) (A.B)

<sup>2</sup>Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville School of Medicine, Louisville, KY, 40202 USA; [adrienne.bushau@louisville.edu](mailto:adrienne.bushau@louisville.edu)

(A.M.B); [krystal.hamorsky@louisville.edu](mailto:krystal.hamorsky@louisville.edu) (K.T.H); [kenneth.palmer@louisville.edu](mailto:kenneth.palmer@louisville.edu) (K.E.P)

<sup>3</sup>Center for Integrative Environmental Health Sciences, University of Louisville School of Medicine, Louisville, KY, USA 40202; [shesh.raai@louisville.edu](mailto:shesh.raai@louisville.edu) (S.N.R)

<sup>4</sup>Biostatistics and Bioinformatics Facility, Brown Cancer Centre, University of Louisville, Louisville, KY 40202, USA

<sup>5</sup>Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY 40202, USA

\*Correspondence: Aruni Bhatnagar, PhD, FAHA ([aruni@louisville.edu](mailto:aruni@louisville.edu))

**COUNTS:**

Abstract: 200 words

Main Text: 2,025

# of Tables: 2

# of Figures: 1

### **AUTHOR CONTRIBUTIONS:**

Conception and Design: A.R. Amraotkar, A. Bhatnagar, R. Keith

Collection, Analysis, or Interpretation of Data: A.R. Amraotkar, R. J. Keith, A. M. Bushau-Sprinkle, K. T. Hamorsky.

Statistical Analysis: Hong Gao and Shesh N. Rai

Drafting of Article: All Authors

Critical Revision for Important Intellectual Content: All authors

### **CORRESPONDING AUTHOR:**

Aruni Bhatnagar, PhD, FAHA

Director, Christina Lee Brown Envirome Institute

Chief, Division of Environmental Medicine

University of Louisville School of Medicine

302 E. Muhammad Ali Blvd, Suite 107, Louisville KY 40202

Email: [Aruni@Louisville.edu](mailto:Aruni@Louisville.edu)

## ABSTRACT

**Background:** The impact of chronic health conditions (CHC) on serostatus post-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is unknown.

**Methods:** We assessed serostatus post-SARS-CoV-2 vaccination among fully vaccinated adult residents of Jefferson County, Kentucky, USA from April 2021 through August 2021. Serostatus was determined by qualitative analysis of SARS-CoV-2 specific Spike IgG antibodies via enzyme-linked immunoassay (ELISA) in peripheral blood samples.

**Results:** Of the 5,178 fully vaccinated participants, 51 were seronegative and 5,127 were seropositive. Chronic kidney disease (CKD) and autoimmune disease showed highest association with negative serostatus in fully vaccinated individuals. The absence of any CHC was strongly associated with positive serostatus. The risk of negative serostatus increased as the total number of pre-existing CHCs increased. Similarly, use of 2 or more CHC related medications was associated with seronegative status.

**Conclusions:** Presence of any CHC, especially CKD or autoimmune disease, increased the likelihood of seronegative status among individuals who were fully vaccinated to SAR-CoV-2. This risk increased with a concurrent increase in number of comorbidities, especially with multiple medications. Absence of any CHC was protective and increased the likelihood of a positive serological response. These results will help develop appropriate guidelines for booster doses and targeted vaccination programs.

**Keywords:** SARS-CoV-2 antibody; antibody response; serology; serostatus; comorbidity

## 1. INTRODUCTION

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its mutated variants continue to increase morbidity and mortality worldwide.(1) Congruent with infection prevention and control measures, wide-spread vaccination is an effective means of containing and ending the Coronavirus Disease 2019 (COVID-19) pandemic.(2) However, in addition to the continued expansion of vaccination efforts, it is important to identify factors that influence vaccine efficacy. Especially with recent reports of waning vaccine effectiveness after 6-8 months.(3-5)

Effectiveness of the vaccines among non-immunocompromised individuals in the US is documented.(6) But, there are sparse data comparing vaccine efficacy between individuals with and without pre-existing comorbidities, and their relative effect on vaccination response. In-vivo neutralization activity is a strong predictor of the protection from COVID-19 acquired from vaccination.(7, 8) Although neutralization immunoassays are highly predictive of immune protection, they are severely limiting for large-scale deployment due to the technical complexities, low throughput, and a delayed turn-around time.(9) Alternately, a high throughput serological testing setup is relatively easy to setup and provides accurate and precise assessment of presence or absence of SARS-CoV-2 Spike protein (IgG) specific antibodies from blood samples. Our group has previously shown that serological tests can be used as a surrogate for immunological response screening.(10) Gaining insights into factors which affect the serological response to vaccines will guide the deployment of boosters worldwide and help identify individuals at greater risk of breakthrough infections. Therefore, we sought to study the effect of comorbidities on serostatus post-SARS-CoV-2 vaccination.

## 2. MATERIALS AND METHODS

### 2.1. *Design and Study Population*

Data for the study were collected under the Co-Immunity Project, which is a federally funded ongoing population-based study for the surveillance of SARS-CoV-2 in Jefferson County,

Kentucky. The study was initiated in June 2020 and has completed 8 rounds of testing through October 2021. The SARS-CoV-2 vaccines were made widely available to the public in Kentucky starting April 2021. Data reported here are from April 2021 through August 2021. Participants were 18 years and older residents of Jefferson County who provided signed consent. This study and all the protocols were approved by the Institutional Review Board of the University of Louisville (IRB # 20.0393).

## **2.2. Vaccination Status**

For analysis, only fully vaccinated participants were included. As per the Centers for Disease Control and Prevention (CDC), participants were considered “Fully Vaccinated” only if their final dose (2<sup>nd</sup> dose for Moderna or Pfizer-BioNTech and 1<sup>st</sup> dose for Janssen) was  $\geq 14$  days prior to the study appointment.(11) All participants in this study were within 9 months of their final vaccination dose.

## **2.3. Health History**

Health history regarding pre-existing chronic health conditions and medications was self-reported by the study participants. History of lupus, rheumatoid arthritis, celiac disease, spondylitis, graves disease, etc. was combined into a single variable “Autoimmune Diseases”. Regular use of medications involved with immune-suppression like steroids, Secukinumab, Baricitinib, Tofacitinib, Methotrexate, etc. was combined into a single variable “Immunosuppressants”. History of all modalities of cancer treatments including chemotherapy, radiation therapy, surgery, immunotherapy, etc. were combined into a single variable “Cancer Treatment”. Use of angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blocker (ARB) was combined into a single variable “ACEi or ARB”.

## **2.4. Human Samples and Serology**

Trained staff collected nasopharyngeal swab and blood finger prick samples. Samples were analyzed for infection by reverse transcription polymerase chain reaction (RT-PCR).(12) Serostatus was determined by measuring levels of SARS-CoV-2 Spike protein specific

immunoglobulin (Ig) G (Spike IgG) antibodies in peripheral blood samples as reported previously.(10) Serostatus was a qualitative assessment (positive or negative) based on the enzyme-linked immunoassay (ELISA) results from above.

## **2.5. Statistical Analysis**

Two study groups were defined *a priori* as: seronegative and seropositive. The primary objective was to compare the univariate relationship of chronic health conditions (CHC) between seronegative versus seropositive statuses. The secondary objective was to examine the adjusted associations between clinical characteristics and seronegative status. Participant characteristics are expressed as mean  $\pm$  standard deviation for continuous variables, and frequency (%) for categorical variables. Relative magnitude of negative serostatus was estimated by odds ratio (OR) and 95% confidence intervals (CI).

For the secondary objective, multivariable logistic regression models were built to calculate the adjusted OR for negative serostatus in participants with CHCs or taking medications. Models were adjusted for age, sex, CHCs, and medications. P-value was considered significant at  $<0.05$ . All statistical analyses were performed using SAS, version 9.4 (SAS Institute, Inc., Cary, North Carolina).


## **3. RESULTS**

### **3.1. Cohort**

Of the 7,046 participants enrolled from April 2021 through August 2021, a total of 1,868 were excluded from the analysis because 802 were unvaccinated, 487 were missing vaccination dates or other vaccination related critical data, 247 were missing critical demographic information or medical history, and 332 were not “Fully Vaccinated” as defined in Methods (Figure 1). The final study dataset included 5,178 participants, of which, 51 were seronegative and 5,127 were seropositive. The general cohort information is presented in Table 1. Briefly, the

mean age was higher in the seronegative group ( $69 \pm 25$  years) as compared to the seropositive group ( $62 \pm 23$  years;  $P=0.024$ ). There was no difference in sex, race, or tobacco use between the two study groups.

**Figure 1.** CONSORT Flow Diagram of Dataset Identification



### 3.2. CHCs and Serostatus

Among those with no-CHC, 21.6% were seronegative, whereas 42.4% were seropositive (OR=0.37, 95% CI: 0.19-0.73; P=0.003) (Table 1). Among those with diabetes, 17.7% were seronegative, whereas 10.6% were seropositive (OR=3.27, 95% CI: 1.35-7.94; P=0.01). Among those with hypertension, 45.1% were seronegative, whereas 33.6% were seropositive (OR=2.9, 95% CI: 1.38-6.11; P=0.003). Among those with heart disease, 13.7% were seronegative, whereas 7.6% were seropositive (OR=3.56; 95% CI: 1.37-9.23; P=0.013). For autoimmune diseases, 31.4% were seronegative, whereas 5.4% were seropositive (OR=11.34, 95% CI: 5.21-24.69; P<0.0001). Among those with chronic kidney disease (CKD), 11.8% were seronegative, and 1.7% were seropositive (OR=13.49, 95% CI: 4.88-37.3; P<0.0001).

Individuals with a composite of any cardiovascular disease (CVD) were 49% seronegative, whereas 36.2% were seropositive (OR=2.93, 95% CI: 1.4-6.11; P=0.003). Similarly, among individuals with a composite of any CHC, 78.4% were seronegative whereas 57.6% were seropositive (OR=2.68, 95% CI: 1.37-5.24; P=0.003).

### 3.3. Medications and Serostatus

History of immunosuppressants (OR=23, 95% CI: 12.1-43.25; P<0.0001) and cancer treatments (OR=12, 95% CI: 4.17-36.88; P=0.001) were also higher in the seronegative group. History of ACEi or ARB was not associated with serostatus (OR=0.82; 95% CI: 0.34-1.99; P=0.66).

**Table 1.** Univariate Comparison of Clinical Characteristics Between Study Groups

Characteristics	Antibody Negative* (n = 51)	Antibody Positive* (n = 5,127)	Odds Ratio (95%CI)	P-Value
Age, Median ± IQR	69 ± 25	62 ± 23		<b>0.024</b>
Sex, Female N (%)	37 (72.6)	3,393 (66.2)		0.34
Race, White N (%)	48 (94.1)	4,457 (86.9)	2.41 (0.75 - 7.74)	0.13



Any Tobacco Use	2 (3.9)	201 (3.9)	1 (0.24 - 4.14)	1.00
<b>Chronic Health Conditions (CHC)</b>				
None, N (%)	11 (21.6)	2,176 (42.4)	0.37 (0.19 - 0.73)	<b>0.003</b>
Diabetes, N (%)	9 (17.7)	544 (10.6)	3.27 (1.35 - 7.94)	<b>0.010</b>
Hypertension, N (%)	23 (45.1)	1723 (33.6)	2.9 (1.38 - 6.11)	<b>0.003</b>
Heart Disease, N (%)	7 (13.7)	389 (7.6)	3.56 (1.37 - 9.23)	<b>0.013</b>
Autoimmune Disease, N (%)	16 (31.4)	279 (5.4)	11.34 (5.21 - 24.69)	<b>&lt;.0001</b>
Cancer, N (%)	5 (9.8)	347 (6.8)	2.85 (0.98 - 8.25)	0.06
Thyroid Disease, N (%)	6 (11.8)	547 (10.7)	2.17 (0.8 - 5.89)	0.13
Chronic Kidney Disease, N (%)	6 (11.8)	88 (1.7)	13.49 (4.88 - 37.3)	<b>&lt;.0001</b>
<b>Composite CHC</b>				
Cardiovascular Disease, N (%)	25 (49.0)	1,856 (36.2)	2.93 (1.4 - 6.11)	<b>0.003</b>
Any CHC, N (%)	40 (78.4)	2,951 (57.6)	2.68 (1.37 - 5.24)	<b>0.003</b>
<b>Medications</b>				
None, N (%)	27 (52.94)	3,852 (75.1)	0.37 (0.21 - 0.65)	<b>0.0003</b>
All Medications, N (%)	24 (47.06)	1,275 (24.9)	2.69 (1.54 - 4.67)	<b>0.0003</b>
ACEI or ARB, N (%)	6 (11.76)	1,041 (20.3)	0.82 (0.34 - 1.99)	0.66
Immunosuppressants, N (%)	17 (33.33)	106 (2.1)	22.88 (12.1 - 43.25)	<b>&lt;.0001</b>
Cancer Treatments, N (%)	4 (7.84)	46 (0.9)	12.41 (4.17 - 36.88)	<b>0.001</b>

**Abbreviations:** ACEI – Angiotensin Converting Enzyme Inhibitor; ARB – Angiotensin Receptor Blocker; CHC – Chronic Health Conditions; IQR – Interquartile Range

\*Serostatus Determined by Presence/Absence of SARS-CoV-2 Spike Protein (IgG) Antibodies in peripheral blood via ELISA

### **3.4. Adjusted Associations Between Clinical Characteristics and Seronegative Status**

Age  $\geq$  65 years, sex, or reported history of tobacco product use were not significantly associated with seronegative status (Table 2). However, the presence of even one reported CHC was significantly associated with seronegative status (OR=2.69; 95%: 1.25-5.79). Similarly, the association between pre-existing CHCs and seronegative status strengthened with

an increase in the number of CHCs from two (OR=2.82; 95%: 1.14-7.0) to three or more (OR=4.52; 95%: 1.68-12.14).

**Table 2.** Multivariable Association Between Clinical Characteristics and SARS-CoV-2 Spike IgG Antibody Negative Status

Characteristics	Referent Group	Odds Ratio	95%CI
Age $\geq$ 65 years	< 65 Years	1.13	0.64 – 1.98
Sex, Female (%)	Male	1.4	0.77 – 2.54
Composite Chronic Health Conditions (CHC)			
1 CHC	No CHC	<b>2.69</b>	<b>1.25 – 5.79</b>
2 CHCs	No CHC	<b>2.82</b>	<b>1.14 – 7.0</b>
$\geq$ 3 CHCs	No CHC	<b>4.52</b>	<b>1.68 – 12.14</b>
Composite Medications			
1 medication	No Medications	1.43	0.76 – 2.71
$\geq$ 2 medications	No Medications	<b>6.08</b>	<b>2.01 – 18.35</b>

Abbreviations: CHC – Chronic Health Conditions; CI – Confidence Interval

#### 4. DISCUSSION

In this study of 5,178 fully vaccinated participants enrolled during the beginning of the Delta variant (B.1.617.2 and AY lineages) spread, we found that those reporting no CHCs were more likely to develop detectable antibody levels (a.k.a., seropositivity) after completing vaccination regimen. Conversely, those reporting a pre-existing comorbid condition were less likely to develop a seropositive status after immunization. The highest risk of not developing a detectable antibody response was seen with CKD, although those reporting CVD, diabetes, or hypertension were also less likely to develop seropositive status after vaccination. The odds of a seronegative status increased with an increase in the number of comorbidities.

More than 10.6 billion COVID-19 vaccine doses have been administered worldwide and most of the “fully vaccinated” population worldwide completed their final dose at least 6-8 months ago.(1) Similarly, most of the adults in the United States who received their first booster dose completed the booster regimen at least 11 months ago.(13) There are growing concerns about waning vaccine effectiveness, including first booster dose, after 6–8-months.(3-5) Therefore it is important to identify factors that may play a role in influencing the vaccine effectiveness. Although it is widely suspected that pre-existing comorbidities play a critical role in determining responses to immunization,(14) few data are available to determine the role of comorbidities on serological response or vaccine efficacy in the public. We found that <1% of our study population failed to develop an appreciable response to the vaccine despite the high rates of diabetes (10.7%), hypertension (33.7%), and cancer (6.8%) in our cohort, which are comparable to national rates of these comorbidities. Neutralization immunoassays are the gold standard to measure the effect of immune protection post-vaccination but have severe logistical limitations for large-scale use, including maintaining a Biosafety Level 3 facility.(9) On the other hand, serological assays can identify presence or absence of SARS-CoV-2 specific antibodies in blood samples in a high throughput setting. Even though positive serology does not ensure the competence of an immune response, there is a significant relationship between a seropositive status and SARS-CoV-2 neutralization potential via microneutralization and Plaque Reduction Neutralization assays (PNA).(10) This suggests that those who fail to establish a measurable seropositive status are more likely to remain vulnerable to SARS-CoV-2 infection. Furthermore, even though a seropositive status does not guarantee successful vaccination effect (i.e., SARS-CoV-2 neutralization), a seronegative status excludes any possibility of virus neutralization.(15)

About 52% adults in the United States have at least 1 CHC and about 27% have multiple CHCs.(16) According to the data presented in our study, almost half of the adult population in the United States has a two-fold chance of being vulnerable to SARS-CoV-2 (or re-infection),

even if they are fully vaccinated. Although diabetes, hypertension, and CVD are well-known risk factors for severe COVID-19 outcomes,(17) our study shows that CKD is the biggest threat, even among fully vaccinated individuals as has been suspected previously.(18, 19) Our findings suggest that presence of these comorbidities significantly increases the likelihood of vaccine failure.

The Global Burden of Disease Study (GBD) has estimated one in five individuals worldwide to be at risk for severe COVID-19, primarily due to their burden of pre-existing CHCs.(18) There is a significant overlap in diseases reported by the GBD and those found to increase the likelihood of a seronegative status in our study.(20) Cancer, a major CHC in GBD, showed a very modest association with seronegative status in our study. However, current treatment for cancer was strongly associated with seronegative status, indicating that treatment status might be a more accurate clinical indicator of impaired immune response rather than a clinical diagnosis of cancer. Some studies have shown a significant association between ACEi or ARB use and risk of SARS-CoV-2 infection and severity of health outcomes.(21, 22) In contrast to that, our study did not find any association, positive or negative, between ACEi or ARB use and serostatus. This suggests that use of ACEi or ARB may not affect vaccine efficacy, even if their use has the potential to influence risk of disease or its severity. Interestingly, our study

Additional work is required to elucidate whether the presence of these comorbidities and other risk factors like smoking influence the effectiveness of the virus neutralization capabilities post-vaccination. The results of such studies will help better shape the guidelines for booster doses and future vaccination programs.

### ***Limitations***

Limitations of the study include a lack of SARS-CoV-2 titer or neutralization data, which was not the primary objective of the study, but can evaluate a continuous relationship between comorbid conditions and antibody titer and neutralization efficacy. Serological assessment is not a

definitive method to measure antibody efficacy, but seropositive status has a strong correlation with virus neutralization potential. The main goal of this study was to identify differences in serostatus among fully vaccinated individuals and was not powered to study the difference between individual vaccines. Finally, this study is cross-sectional in design, which does not allow us to report change over-time.

## **5. CONCLUSIONS**

Among fully vaccinated individuals, presence of any CHC, especially CKD or autoimmune disease, increased the likelihood of seronegative status by multi-fold. This risk increased with a concurrent increase in number of comorbidities. CHCs requiring long-term treatment, especially immunosuppressants or cancer treatments, increased the likelihood of a seronegative status. Absence of any CHC was protective and increased the likelihood of a positive serological response post-vaccination. These results will help develop appropriate guidelines for booster doses and targeted vaccination programs.

## **ACKNOWLEDEMENTS**

We would like to thank all study participants who generously consented to participate in this study. We would also like to thank the City of Louisville Metro, Kentucky and various other collaborators and partners who helped us complete this important study.

## **INFORMED CONSENT STATEMENT**

All the study participants provided signed consent. This study and all the protocols were approved by the Institutional Review Board of the University of Louisville (IRB # 20.0393), which conforms to the standards currently applied in the United States.

## **FUNDING**

Louisville-Jefferson County Metro Government as a component of the Coronavirus Aid, Relief, and Economic Security (CARES) Act – Recipient: Aruni Bhatnagar

Centers for Disease Control and Prevention (# 75D30121C10273) – Recipient: Aruni Bhatnagar

James Graham Brown Foundation – Recipient: Aruni Bhatnagar

Owsley Brown II Family Foundation – Recipient: Aruni Bhatnagar

## **DATA AVAILABILITY STATEMENT**

Primary de-identified data supporting the findings of this study are available through the corresponding author (Aruni Bhatnagar: [Aruni.bhatnagar@louisville.edu](mailto:Aruni.bhatnagar@louisville.edu)) upon request.

## **CONFLICT OF INTEREST**

All authors have no financial, personal, or other conflicts of interests to disclose.

## REFERENCES

1. World Health Organization (W.H.O). Who Coronavirus (Covid-19) Dashboard. (2021).
2. Centers for Disease Control and Prevention (C.D.C). Covid-19. , (2021).
3. Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of Covid-19 Booster Vaccines against Covid-19-Related Symptoms, Hospitalization and Death in England. *Nat Med* (2022) 28(4):831-7. Epub 2022/01/20. doi: 10.1038/s41591-022-01699-1.
4. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning Immunity after the Bnt162b2 Vaccine in Israel. *N Engl J Med* (2021) 385(24):e85. Epub 2021/10/28. doi: 10.1056/NEJMoa2114228.
5. Mahase E. Covid-19: Booster Vaccine Gives "Significant Increased Protection" in over 50s. *BMJ* (2021) 375:n2814. Epub 2021/11/19. doi: 10.1136/bmj.n2814.
6. Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, et al. Comparative Effectiveness of Moderna, Pfizer-Biontech, and Janssen (Johnson & Johnson) Vaccines in Preventing Covid-19 Hospitalizations among Adults without Immunocompromising Conditions - United States, March-August 2021. *MMWR Morb Mortal Wkly Rep* (2021) 70(38):1337-43. Epub 2021/09/24. doi: 10.15585/mmwr.mm7038e1.
7. Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralising Antibody Titres as Predictors of Protection against Sars-Cov-2 Variants and the Impact of Boosting: A Meta-Analysis. *Lancet Microbe* (2022) 3(1):e52-e61. Epub 2021/11/23. doi: 10.1016/S2666-5247(21)00267-6.

8. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing Antibody Levels Are Highly Predictive of Immune Protection from Symptomatic Sars-Cov-2 Infection. *Nat Med* (2021) 27(7):1205-11. Epub 2021/05/19. doi: 10.1038/s41591-021-01377-8.
9. Bewley KR, Coombes NS, Gagnon L, McInroy L, Baker N, Shaik I, et al. Quantification of Sars-Cov-2 Neutralizing Antibody by Wild-Type Plaque Reduction Neutralization, Microneutralization and Pseudotyped Virus Neutralization Assays. *Nat Protoc* (2021) 16(6):3114-40. Epub 2021/04/25. doi: 10.1038/s41596-021-00536-y.
10. Hamorsky KT, Bushau-Sprinkle AM, Kitterman K, Corman JM, DeMarco J, Keith RJ, et al. Serological Assessment of Sars-Cov-2 Infection During the First Wave of the Pandemic in Louisville Kentucky. *Sci Rep* (2021) 11(1):18285. Epub 2021/09/16. doi: 10.1038/s41598-021-97423-z.
11. Centers for Disease Control and Prevention (C.D.C). Fully Vaccinated. (2021).
12. Centers for Disease Control and Prevention (C.D.C). Cdc Diagnostic Tests for Covid-19. (2020).
13. Fast HE, Zell E, Murthy BP, Murthy N, Meng L, Scharf LG, et al. Booster and Additional Primary Dose Covid-19 Vaccinations among Adults Aged  $\geq 65$  Years - United States, August 13, 2021-November 19, 2021. *MMWR Morb Mortal Wkly Rep* (2021) 70(50):1735-9. Epub 2021/12/17. doi: 10.15585/mmwr.mm7050e2.
14. Kompaniyets L, Pennington AF, Goodman AB, Rosenblum HG, Belay B, Ko JY, et al. Underlying Medical Conditions and Severe Illness among 540,667 Adults Hospitalized with Covid-19, March 2020-March 2021. *Prev Chronic Dis* (2021) 18:E66. Epub 2021/07/02. doi: 10.5888/pcd18.210123.



15. Aziz NA, Corman VM, Echterhoff AKC, Muller MA, Richter A, Schmandke A, et al. Seroprevalence and Correlates of Sars-Cov-2 Neutralizing Antibodies from a Population-Based Study in Bonn, Germany. *Nat Commun* (2021) 12(1):2117. Epub 2021/04/11. doi: 10.1038/s41467-021-22351-5.
16. Boersma P, Black LI, Ward BW. Prevalence of Multiple Chronic Conditions among US Adults, 2018. *Prev Chronic Dis* (2020) 17:E106. Epub 2020/09/19. doi: 10.5888/pcd17.200130.
17. Li J, He X, Yuan Y, Zhang W, Li X, Zhang Y, et al. Meta-Analysis Investigating the Relationship between Clinical Features, Outcomes, and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) Pneumonia. *Am J Infect Control* (2021) 49(1):82-9. Epub 2020/06/17. doi: 10.1016/j.ajic.2020.06.008.
18. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, Regional, and National Estimates of the Population at Increased Risk of Severe Covid-19 Due to Underlying Health Conditions in 2020: A Modelling Study. *Lancet Glob Health* (2020) 8(8):e1003-e17. Epub 2020/06/20. doi: 10.1016/S2214-109X(20)30264-3.
19. Council E-E, Group EW. Chronic Kidney Disease Is a Key Risk Factor for Severe Covid-19: A Call to Action by the Era-Edta. *Nephrol Dial Transplant* (2021) 36(1):87-94. Epub 2020/12/20. doi: 10.1093/ndt/gfaa314.
20. Diseases GBD, Injuries C. Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019. *Lancet* (2020) 396(10258):1204-22. Epub 2020/10/19. doi: 10.1016/S0140-6736(20)30925-9.
21. Armstrong K, Soltoff A, Rieu-Werden M, Metlay J, Haas J. Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Associated with Lower Risk of

Covid-19 in Household Contacts. *PLoS One* (2021) 16(3):e0247548. Epub 2021/03/03. doi: 10.1371/journal.pone.0247548.

22. Pan M, Vasbinder A, Anderson E, Catalan T, Shadid HR, Berlin H, et al. Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for Covid-19. *J Am Heart Assoc* (2021) 10(24):e023535. Epub 2021/12/11. doi: 10.1161/JAHA.121.023535.